Cardiovascular Implantable Electronic Devices -> Monitoring & Outcomes: -> Monitoring & Follow-up D-PO05 - Poster Session V (ID 39) Poster

D-PO05-089 - Clinical Characteristics And Treatment Outcomes: A 5 Year Experience From A Large, Racially Diverse Cardiac Sarcoidosis Registry (ID 542)


Background: There remains a paucity of literature leveraging large cohorts of cardiac sarcoidosis (CS) patients.
Objective: To present the patient characteristics and outcomes of a large, racially diverse, new registry of CS patients.
Methods: Using automated chart review from January 2014 - September 2019 of our electronic medical record, we created a registry of patients with CS. Patients were included if they had clinical suspicion of CS and corroborating endomyocardial biopsy, PET scan, or cardiac MRI.
Results: A total of 45 patients were identified, with mean age at diagnosis of 51 ±10.5 years. Nearly half the patients were black (47.7%), approximately a third had preserved systolic function (31.1%), and 28.9% had severe systolic dysfunction. Nineteen (42.2%) had infranodal conduction disease. Extra-cardiac sarcoidosis was present in 33 (73.3%) patients. Methods of CS diagnosis were endomyocardial biopsy (3, 6.7%), PET scan (30, 66.7%), and cardiac MRI (24, 53.3%). Of the 38 patients with cardiac implantable electronic devices (CIED), 13 (28.9%) had their devices placed prior to CS diagnosis, with a median time from CIED placement to CS diagnosis of 9.5 months (IQR 2.6 - 41.6 months). Twenty-five (55.6%) had their devices placed after CS diagnosis, with a median time from diagnosis to device placement of 2.8 months (IQR 0.2 - 9.1 months). Seven (15.6%) patients received a device upgrade after CS diagnosis, with median time from initial implant to upgrade of 50.9 months (IQR 32.6 - 93.9 months). Immunosuppressive (for extra cardiac sarcoidosis) and antiarrhythmic medical therapy were used in 20.0% each of patients prior to diagnosis of CS. Defibrillators were placed in 32 (71.1%) patients, and of them, 7 (21.9% of defibrillator patients, 15.6% of total CS patients) received appropriate defibrillator therapy. Inappropriate therapies for rapid atrial fibrillation or noise from lead fracture were delivered in 3 (6.7%) patients. During a mean follow-up time of 2.8 years (IQR 1.6 - 6.0 years), one patient expired, and one received heart transplant.
Conclusion: We report the patient characteristics of a new, large registry of racially diverse CS patients, including medical comorbidities, medical therapy, and CIED-related data.